...
首页> 外文期刊>European journal of anaesthesiology >A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient.
【24h】

A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient.

机译:比较舒芬太尼与瑞芬太尼在病态肥胖患者中进行腹腔镜胃成形术的随机试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVE: This prospective, randomised double-blind study compared the effects of target control infusion (TCI) of sufentanil and remifentanil on the quality of recovery and post-operative pain control in morbidly obese patients undergoing laparoscopic gastroplasty. METHODS: Following institutional Ethics Committee approval and written informed consent, 100 morbidly obese patients were randomised to receive either TCI sufentanil (0.3 ng ml(1); S-group; N = 50) or TCI remifentanil (3 ng ml(1); R-group; N = 50) in combination with desflurane (O/air mixture: FiO, 50%). Quality of recovery was estimated by means of the modified Aldrete score and by the ability to perform psychomotor tests with the same competence post-operatively as pre-operatively. Post-operative pain was evaluated by the quantity of piritramide needed to achieve a visual analogue scale (VAS) less than 3. Statistical analysis was performed using an unpaired Student's t-test, Mann-Whitney U-test and chi(2) test, as appropriate. RESULTS: Patient and surgical characteristics were similar among groups. In the R-group, time to extubation was significantly shorter, but VAS significantly higher than that in the S-group (P < 0.01). Quality of recovery and duration of post-anaesthesia care unit stay were comparable between groups (S-group: 119 +/- 27 min and R-group: 119 +/- 35 min). Piritramide consumption during the first 4 post-operative hours was higher in the R-group than in the S-group [S-group (median, range): 11.5 mg, 5.5-16.0; R-group: 18.0 mg, 14-22, P < 0.01], but not later on. CONCLUSION: In the conditions of the present study, although TCI sufentanil resulted in slower awakening than TCI remifentanil, it was associated with a better quality of recovery.
机译:背景与目的:这项前瞻性,随机,双盲研究比较了舒芬太尼和瑞芬太尼的靶控输注(TCI)对病态肥胖的腹腔镜胃成形术患者的恢复质量和术后疼痛控制的影响。方法:经机构伦理委员会批准并获得知情同意书后,将100例病态肥胖患者随机分为TCI舒芬太尼(0.3 ng ml(1); S组; N = 50)或TCI瑞芬太尼(3 ng ml(1));或R-基团; N = 50)与地氟醚组合(O /空气混合物:FiO,50%)。通过修改后的Aldrete评分以及通过术后进行与术前相同能力进行心理运动测试的能力来评估恢复质量。术后疼痛的评估通过达到视觉模拟量表(VAS)小于3所需的吡咯酰胺的量进行。统计学分析使用不配对的Student t检验,Mann-Whitney U检验和chi(2)检验进行,作为适当的。结果:各组患者和手术特点相似。 R组拔管时间明显缩短,但VAS显着高于S组(P <0.01)。各组之间的恢复质量和麻醉后护理单元的停留时间相当(S组:119 +/- 27分钟,R组:119 +/- 35分钟)。 R组术后4小时的吡咯酰胺消耗量高于S组[S组(中位数,范围):11.5 mg,5.5-16.0; R-组:18.​​0 mg,14-22,P <0.01],但以后没有。结论:在本研究的条件下,尽管TCI舒芬太尼比TCI瑞芬太尼引起的唤醒更慢,但其恢复质量更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号